SeraCare Life Sciences, Inc. Has Agreed To Be Taken Private By Linden Capital Partners

  • Do you own shares of SeraCare Life Sciences, Inc. (NASDAQ: SRLS)?
  • Did you buy any shares before February 13, 2012?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is a national law firm with decades of combined legal experience.  R & L is investigating potential claims against the board of directors of SeraCare Life Sciences, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company's entry into an agreement to be acquired and taken private by Linden Capital Partners for approximately $82 million.

Click here to read the full press release.

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) Investigated by Rigrodsky & Long, P.A. Over Its Agreement To Be Taken Private By Linden Capital Partners

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of SeraCare Life Sciences, Inc. (“SeraCare” or the “Company”) (Nasdaq: SRLS) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by an affiliate of Linden Capital Partners, a Chicago-based private equity firm, in a transaction with an approximate value of $82 million.

Under the proposed agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share.  The deal, assuming all conditions are met and it is approved by shareholders and the U.S. Securities and Exchange Commission, is expected to close in the second quarter of 2012.

The investigation concerns whether SeraCare’s board of directors adequately shopped the Company to obtain the best price possible for SeraCare shareholders before entering into the agreement with Linden Capital Partners.  Indeed, according to Yahoo! Finance, at least one analyst has set a price target of $5.00 per share for SeraCare’s stock.

If you own the common stock of SeraCare and purchased your shares before February 13, 2012, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Scott J. Farrell, Esquire, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout theUnited States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our Website |  Our Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.